Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : AZNCF save search
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
Published: 2024-02-08 (Crawled : 12:00) - prnewswire.com
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: -8.5%
H: 2.46%
C: 2.46%
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.2%
H: 1.37%
C: 0.68%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -6.81%
H: 3.02%
C: 2.42%
fda granted designation eplontersen
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
Published: 2023-10-13 (Crawled : 13:00) - prnewswire.com
PYXS | $4.155 -8.28% -9.03% 670K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 2.56%
C: 2.56%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.15%
H: 0.0%
C: 0.0%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.63%
H: 4.97%
C: 2.76%
MRUS | $39.83 -1.58% -1.61% 800K
|
Health Technology
|
| O: 0.47%
H: 1.7%
C: -0.38%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.59%
H: 0.62%
C: -0.56%
fda year review cancer pancreatic
Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate
Published: 2023-07-11 (Crawled : 14:00) - biospace.com/
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 1.25%
H: 3.41%
C: -1.43%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.28%
H: 0.25%
C: -0.23%
fda lung drug candidate cancer cell designation therapy fast track designation
Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer
Published: 2023-06-28 (Crawled : 14:00) - biospace.com/
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -2.36%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 14.85%
H: 1.18%
C: -7.27%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.29%
H: 0.13%
C: -0.7%
reqorsa fda lung cancer cell treatment designation therapy fast track designation
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
Published: 2022-01-03 (Crawled : 15:00) - biospace.com/
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.49%
H: 1.06%
C: -2.49%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 16.79%
H: 0.0%
C: 0.0%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: 0.07%
keytruda fast track designation treatment fda fast track gene therapy cel fda fast track lung cancer therapy cancer designation
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.